Breakthru Medicine

About Breakthru Medicine

Breakthru Medicine is dedicated to pioneering next-generation oncology treatments through scientific excellence and proven drug development expertise. The company aims to deliver hope to patients and returns to investors by advancing innovative cancer therapies to address critical unmet clinical needs.

Products & Services

Innovative Cancer Therapeutics:A portfolio of cancer therapies designed to meet critical clinical needs, developed through cutting-edge science and capital-efficient strategies.

Multi-pronged Oncology Programs:Multiple independent programs offering pathways to breakthrough treatments.

Lead Program:Targeting clinical trials in early 2027.

Platform-enabled Discovery:Technology to accelerate identification and validation of critical-need therapeutic targets.

Specialties

Oncology Drug Development Cancer Therapeutics Platform-enabled Drug Discovery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 60000000 MR: - FA: $60M FAN: 60000000	D: 2026-01-29 FD: 2026-01-29	3 investors

Series A Latest

2026-01-29

$60.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Steve Potts

Chief Executive Officer

M

Mark Mulvihill

Chief Science Officer

B

Brian Barnett

Chief Medical Officer

M

Mark Gergen

Board Chair

M

Mike Amend

Investor

D

David Morehead

Board Member

View 9 more team members with Pro

Unlock Full Team Directory

Recent News